Clinical Trials Logo

Clinical Trial Summary

This is a pilot study to assess the cell adequacy and quality of Pap smears and adequacy of samples for HPV DNA virus test done after application of 5%acetic acid in a VIA test.Normally a Pap test and HPV DNA test is performed before application of acetic acid. It is assumed that application of acetic acid may alter the cell adequacy of Pap test and HPV DNA test, if any of the above tests is done immediately after VIA test.The present study aims to see the effect of 4-5% acetic acid [vinegar] on the cell adequacy and quality of Pap smear and sample adequacy for HPV DNA test.


Clinical Trial Description

Aim (of pilot study):

To evaluate the cell adequacy and smear quality of Pap smears and adequacy of samples for HPV HC 2 collected before and after application of acetic acid.

Objective of Pilot study-

1. Agreement between the results of HC2 on cervical samples obtained from women before and 5 to 10 mins after VIA test

2. Correlation between RLU/ cutoff ratio of HC2 on cervical samples obtained from women before and 5 to 10 mins after VIA test.

3. Agreement between the results of cytology on cervical smears obtained immediately before and 5 to 10 mins after VIA test from the same women.

Methodology:

Design: Pilot study

Study Duration: Three months

Study Site: Preventive Oncology screening clinic, Tata Memorial Hospital

Sample Size calculation and power estimates:

For the pilot study, sampling method is a convenience sample of 50 consecutive eligible women attending the Preventive Oncology screening clinic and consenting to participate in the study. These women will be randomly allocated using lottery method (wherein 25 chits with HPV and 25 chits with cytology written inside will be placed). For every participant woman a chit will be picked up and the woman will be allotted to either HPV or cytology testing depending on the message in the chit. Thereafter the chit will be discarded.

In 25 samples Pap smears will be collected before and after application of acetic acid. Steps mentioned below.

In rest 25 samples HPV DNA will be collected before and after application of acetic acid. Steps mentioned below.

Step 1: A per speculum examination will be performed on eligible women attending the Preventive Oncology screening clinic and the findings of the same will be recorded.

Step 2: Pap smear will be collected - Smear 1. OR Cervical cell samples will be collected for HPV HC II - HPV sample 1. Step 3: VIA will be performed and the findings will be noted. Step 4: A second Pap smear will be collected 5 to 10 minutes after performing VIA when the woman is still on the examination table by the same provider- Smear 2.

OR Cervical cell samples will be collected for HPV HC II - HPV sample 2. Step 5: The smears will be submitted to the cytology department for evaluation. The HPV HC II samples will be submitted to the Microbiology department for evaluation.

Step 6: The cytologist reading the smear will be blinded as to which smear was taken before and which was taken after the application of acetic acid. The same cytologist will read the pre-VIA and the post-VIA smears.

Similarly, the Microbiology department staff will be blinded as to which HPV sample was taken before and which was taken after the application of acetic acid. The paired samples will be analyzed at the same laboratory in the same batch of testing.

Step 7: The screen negative women will undergo routine follow-up. The screen positive women will undergo Colposcopy, guided biopsy and further management according to the Tata Memorial Hospital protocol.

Analysis of the variables Data entry will be done in the Department of Preventive Oncology, Tata Memorial Hospital using SPSS version 18. Checks for consistency, data safety and analysis will be carried out at regular intervals. Both descriptive and inferential statistics will be generated for describing variables under the study objectives. Agreement in HC2 results between pre-VIA and post-VIA samples will be estimated using kappa statistics. Similarly, agreement in pap results between pre-VIA and post-VIA samples will be estimated using kappa statistics. Sensitivity and specificity of HC2 test and pap test in detecting CIN2+ lesions will be calculated using negative colposcopy or biopsy as the gold standard and will be compared between the pre and post VIA samples. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02363244
Study type Observational
Source Tata Memorial Hospital
Contact
Status Completed
Phase
Start date May 2015
Completion date December 2015

See also
  Status Clinical Trial Phase
Completed NCT00339989 - Cervical Cancer Early Endpoints and Determinants
Active, not recruiting NCT05580341 - Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Phase 3
Recruiting NCT03872739 - To Compare Intravenous and Oral Hydration of the Prevention for CIN in Elderly Patients Undergoing Intravenous CECT N/A
Completed NCT01766284 - Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix N/A
Recruiting NCT02116920 - HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening N/A
Enrolling by invitation NCT01836588 - New Gentle Biopsy Method of Cervix Lesions Using Superficial Curettage/Protocol ID: CX-CUR N/A
Completed NCT00289029 - A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography Phase 4
Recruiting NCT06261879 - Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood N/A
Completed NCT03239223 - Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Phase 1
Completed NCT03791606 - Risk Factors,PREvention and OutComes for CI-AKI in PatientS undErgoing PCI at Intensive Care Unit(PRECISE-ICU)
Completed NCT04809727 - Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy N/A